Chiron Appoints Richard Wills to Board of Directors

Chiron Appoints Richard Wills to Board of Directors
Tektronix CEO Brings Extensive Product Development and Global Marketing
Experience to Chiron Board 


EMERYVILLE, Calif., Sept. 9  /PRNewswire-FirstCall/ -- Chiron Corporation
(NASDAQ:CHIR) today announced that Richard Wills, age 49, has been appointed to
the company's board of directors.  Mr. Wills is chief executive officer and
chairman of the board of Tektronix Inc., a technology company providing
measurement solutions to the communications, computer and semiconductor
industries worldwide.

"As a sitting CEO of a technology-based company similar to Chiron in size and
scope, Mr. Wills brings valuable business experience and great enthusiasm to
Chiron's board of directors," said Howard Pien, Chiron's chief executive
officer and chairman of the board.  "We look forward to the contributions
Richard will make as Chiron continues to execute on its business strategy,
implementing pioneering science to improve human health worldwide."

Richard Wills became president and chief executive officer of Tektronix Inc. in
2000, after more than 20 years with the company.  In his time at Tektronix,
Wills has held a variety of executive-level positions in marketing, product
development and product-line management.  He played a key role in building
Tektronix's sales and marketing presence in Europe, the company's largest
market outside the United States, and in establishing the extensive global
marketing capabilities of Tektronix in the Pacific and the United States. 
Tektronix manufactures more than 1,000 products and maintains operations in
North and South America, Europe and Asia Pacific, with manufacturing sites,
development centers and distributors in more than 20 countries worldwide.

About Chiron

Through its global Blood Testing, Vaccines and BioPharmaceuticals businesses,
Chiron Corporation addresses human suffering with more than 50 diverse products
to detect, prevent and treat disease worldwide.  The company's consistent
success has come from its pioneering science, skill in delivering innovations
in biotechnology and disciplined business approach. Chiron believes that
science has the power to improve people's lives and harnesses that power to
transform human health. For more information about Chiron, please visit
http://www.chiron.com/.

This year, Chiron Vaccines celebrates 100 years of advancing medicine with the
anniversary of two founding companies.  In 1904, Emil von Behring and Achille
Sclavo independently started companies in Germany and Italy, respectively,
dedicated to the research, development and manufacture of vaccines to protect
humanity from infectious disease.  As the fifth-largest vaccine manufacturer in
the world, Chiron remains dedicated to the legacies of von Behring and Sclavo
to prevent disease and develop new vaccines to improve human health globally.

This news release contains forward-looking statements, including statements
regarding sales growth, product development initiatives, new product
indications, new product marketing, acquisitions, and in- and out-licensing
activities that involve risks and uncertainties and are subject to change.  A
full discussion of the company's operations and financial condition, including
factors that may affect its business and future prospects, is contained in
documents the company has filed with the SEC, including the form 10-Q for the
quarter ended June 30, 2004, and the form 10-K for the year ended December 31,
2003, and will be contained in all subsequent periodic filings made with the
SEC.  These documents identify important factors that could cause the company's
actual performance to differ from current expectations, including the outcome
of clinical trials, regulatory review and approvals, manufacturing
capabilities, intellectual property protections and defenses, stock-price and
interest-rate volatility, and marketing effectiveness.  In particular, there
can be no assurance that Chiron will increase sales of existing products,
successfully develop and receive approval to market new products, or achieve
market acceptance for such new products.  There can be no assurance that
Chiron's out-licensing activities will generate significant revenue, nor that
its in-licensing activities will fully protect it from claims of infringement
by third parties.  In addition, the company may engage in business
opportunities, the successful completion of which are subject to certain risks,
including shareholder and regulatory approvals and the integration of
operations.

Consistent with SEC Regulation FD, we do not undertake an obligation to update
the forward-looking information we are giving today. 

DATASOURCE: Chiron Corporation



CONTACT:  Chiron Corporate Communications & Investor Relations, Media,

[phone], or Investors, [phone]



Web site:  http://www.chiron.com/ 

Copyright